The metabolic score for insulin resistance as a predictor of clinical outcome in stroke patients treated by intravenous thrombolysis

Neurol Sci. 2023 Oct;44(10):3587-3594. doi: 10.1007/s10072-023-06848-z. Epub 2023 May 19.

Abstract

Background and purpose: Insulin resistance is associated with clinical outcomes among patients with ischemic stroke. We aimed to investigate the association between metabolic score for insulin resistance (METS-IR) and clinical outcomes in stroke patients treated by intravenous thrombolysis (IVT).

Methods: We recruited participants treated with IVT from a prospective registry including 3 stroke centers. Poor outcome was defined as a modified Rankin scale score ≥ 3 points at 90 days after the index stroke. We performed logistic regression models to investigate the association between METS-IR and the risk of poor outcome. We used the receiver operative characteristic to assess the discriminative ability and the restricted cubic spline to explore the relationship between METS-IR and the poor outcome.

Results: This study enrolled a total of 1074 patients (median age, 68; 63.8% male). Three hundred sixty (33.5%) patients had poor outcome after IVT. METS-IR was associated with the risk of the poor outcome with the increase of confounding factors in models (odds ratio [OR], 1.078; 95% confidence interval [CI], 1.058-1.099; P < 0.001). The area under the curve for METS-IR for predicting the poor outcome was 0.790 (95% CI, 0.761-0.819). The restricted cubic spline revealed an increasing and non-linear association between METS-IR and the poor outcome (P for non-linearity < 0.001).

Conclusion: Our study found that METS-IR was associated with an increased risk of poor outcome after IVT. Further studies are warranted to investigate the efficacy of anti-diabetic agents regarding IR on clinical outcomes after IVT.

Keywords: Insulin resistance; Intravenous thrombolysis; Ischemic stroke; Metabolic score for insulin resistance.

MeSH terms

  • Administration, Intravenous
  • Aged
  • Brain Ischemia* / complications
  • Brain Ischemia* / drug therapy
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Insulin Resistance*
  • Logistic Models
  • Male
  • Stroke* / complications
  • Thrombolytic Therapy / adverse effects
  • Treatment Outcome

Substances

  • Fibrinolytic Agents